Abstract. Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. The aim of this study was to evaluate whether there are differences in the clinical characteristics and survival between patients with advanced HCC with extrahepatic metastasis who received and those who did not receive previous treatment. Between April, 1998 and April, 2012, a total of 419 HCC patients with extrahepatic metastasis (81 previously untreated and 338 previously treated) were enrolled in this study. The differences in the clinical characteristics, including metastatic sites, were compared between the two groups. In addition, the prognostic predictors among all the patients and among the 81 previously untreated patients were analyzed. The distribution of the major metastatic sites was similar in the two groups; the most frequent site of extrahepatic metastasis was the lungs, followed by the bones, lymph nodes and adrenal glands. The median survival time (MST) among the 419 patients was 6.8 months. The 1-, 2-, 3-and 5-year survival rates were 31.6, 15.3, 9.5 and 2.3%, respectively. No significant differences in survival were observed between patients who received and those who did not receive previous treatment. The multivariate analysis revealed that the Child-Pugh classification, white blood cell count, neutrophil-lymphocyte ratio (NLR) and primary tumor stage were independent predictors of survival for all the patients and for the 81 previously untreated patients. Differences in the clinical characteristics of patients with advanced HCC with extrahepatic metastasis were identified between patients who received and those who did not receive previous treatment. Furthermore, intrahepatic tumor status, Child-Pugh classification, white blood cell count and NLR were demonstrated to be independent predictors of survival in HCC patients with extrahepatic metastasis.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Recent advances in imaging technology and implementation of surveillance programs for high-risk patients have led to increased detection of early-stage HCC, making curative therapies possible in some patients (1, 2) . However, the long-term survival of HCC patients remains unsatisfactory, due to the high frequency of intra-and extrahepatic recurrence (3, 4) . In particular, the development of advanced HCC with extrahepatic metastasis hinders the use of curative therapies, such as surgical resection or radiofrequency ablation, therefore contributing to poor survival. Prior to the approval of sorafenib, several systemic chemotherapeutic regimens had been evaluated for patients with advanced HCC, although no effective therapeutic protocols were identified (5, 6) . Two randomized placebo-controlled trials demonstrated a survival benefit associated with sorafenib for patients with advanced HCC, including those with extrahepatic metastasis (7, 8) . As a result, sorafenib is currently considered to be the standard treatment for advanced HCC in the United States, Europe, Japan and a number of other countries (9, 10) . However, although sorafenib appears to prolong survival, this benefit remains unsatisfactory. Therefore, the development of novel agents and/or combinations is required for patients with advanced HCC with extrahepatic metastasis. To design optimal therapies, it is crucial to understand the clinical characteristics and prognostic factors of these patients.
In our clinic, we encountered several HCC patients whose disease progressed to extrahepatic metastasis, despite the administration of appropriate, repeated treatment for intrahepatic tumors, whereas we also encountered patients who were initially diagnosed with HCC with extrahepatic metastasis at presentation and, therefore, have not been previously treated for HCC. As regards patients with advanced HCC with extrahepatic metastasis, several previous studies only reported the clinicopathological characteristics and prognosis of patients with HCC recurrence or a combined set of previously treated and untreated patients (11) (12) (13) (14) 
Diagnosis of HCC and evaluation of extrahepatic lesions.
The diagnosis of HCC was radiologically confirmed by hyperintensity in the arterial phase and washout in the venous and delayed phase, using either contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) (9) and̸or by elevated serum levels of α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP). Tumor biopsy was performed in cases in which imaging findings were not consistent with the characteristic features of HCC, or when tumor marker levels were not elevated. To evaluate extrahepatic metastasis, pulmonary lesions were detected on chest X-ray or chest CT, which were routinely performed at the first visit or every 3-6 months during the follow-up period.
Additional examinations, such as bone scintigraphy and brain CT or MRI, were indicated upon development of symptoms attributable to extrahepatic metastasis. These examinations were also conducted when AFP and/or DCP levels were elevated and the elevation(s) could not be attributed to the status of the intrahepatic lesion(s). Positron emission tomography/CT studies were performed as a supplemental examination.
Follow-up and endpoint. Following HCC diagnosis, each patient was carefully followed up with respect to intrahepatic lesions and extrahepatic metastases. Serum biochemistries, AFP and DCP levels were measured and ultrasonography was performed every 1-2 months. Contrast CT or MRI was performed every 2-6 months. Other imaging modalities were used as necessary. The endpoint of this study was the date of death, or last follow-up visit; the closing date was August, 2012. The median duration of the follow-up was 5.8 months (range, 0.2-111.9 months).
Statistical analysis. The continuous variables are expressed as median values (range). A comparison analysis between
patients who received and those who did not receive previous treatment was performed using the Chi-square test for discrete variables and the Mann-Whitney U test for continuous variables. Overall survival was determined by the Kaplan-Meier analysis and the differences between subgroups were compared with log-rank tests. A Cox proportional hazards stepwise model was used for univariate and multivariate analysis, in order to identify any independent variables associated with overall survival. Data from these models are expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). All P values were two-tailed and P<0.05 was considered to indicate a statistically significant difference. The statistical analysis was performed using SPSS software, version 20 (SPSS, Inc., Chicago, IL, USA).
Results

Clinical characteristics of patients.
A comparison of the clinical characteristics of patients who received and those who did not receive previous treatment is shown in Table I . Previously treated patients were significantly more likely to have HCV infection, Child-Pugh class B+C and a low primary tumor stage, compared to previously untreated patients. Previously untreated patients exhibited a significantly lower neutrophil-lymphocyte ratio (NLR) and higher aspartate aminotransferase (AST) levels, white blood cell counts, platelet counts and DCP levels, compared to previously treated patients. The major metastatic sites, which were the lungs, bones, lymph nodes and adrenal glands were similar in the two groups.
Survival and predictive factors in all the patients. The cumulative survival curve of the 419 patients is shown in Fig. 1 . The median survival time (MST) for these patients was 6.8 months. The 1-, 2-, 3-and 5-year survival rates were 31.6, 15.3, 9.5 and 2.3%, respectively. A Cox proportional hazards regression analysis was performed to identify independent predictors of survival (Table II) . Survival and predictive factors in 81 previously untreated patients. The cumulative survival curve of the 81 patients who did not receive previous treatment is shown in Fig. 2 . The MST for these patients was 7.4 months. The 1-, 2-, 3-and 5-year survival rates were 33.7, 18.8, 11.9 and 2.3%, respectively. No significant differences in survival between patients who received and those who did not receive previous treatment were observed (P=0.369). A Cox proportional hazards regression analysis was performed to identify independent predictors of survival (Table III 
Discussion
It has not been determined whether previous treatment affects the clinical characteristics and prognosis in patients with advanced HCC and extrahepatic metastasis. In this study, we aimed to evaluate whether there are differences between patients with advanced HCC and extrahepatic metastasis who received and those who did not receive previous treatment.
Our results revealed differences in various clinical characteristics between these two groups of patients. Previously treated patients were more likely to exhibit low white blood cell counts, low platelet counts and poor liver function compared to previously untreated patients. A possible explanation for this observation is that leukocytopenia and thrombocytopenia may have been caused by previously administered anticancer drugs, as several patients had repeatedly undergone TACE and HAIC for intrahepatic tumors. In addition, repeated cancer recurrence and various treatments for intrahepatic tumors may have contributed to decreased liver function. Of note, previously untreated patients had more advanced-stage intrahepatic tumors compared to previously treated patients. Previous studies suggested that residual HCC following various treatments is associated with increased malignant potential compared to untreated HCC (16) (17) (18) . Therefore, we suggest that aggressive treatment may result in earlier extrahepatic metastasis, despite a less advanced intrahepatic tumor stage, in previously treated patients. In this study, no significant differences in survival between the two groups were observed, although the groups differed in liver function and intrahepatic tumor stage. A possible explanation for this lack of difference is that worse liver function and an increased malignant potential of previously treated patients may offset the more advanced stage of intrahepatic tumors of previously untreated patients. The major sites of HCC metastasis included the lungs, lymph nodes, bones and adrenal glands (13, 14, (19) (20) (21) . Yoo et al (20) reported that the most frequent metastatic sites in 251 previously untreated HCC patients with extrahepatic metastasis were the lungs (67.3%), lymph nodes (37.5%), bones (18.3%) and adrenal glands (7.6%). Jun et al (14) indicated that in HCC patients with extrahepatic recurrence following hepatic resection, frequent metastatic sites included the lungs (41.9%), lymph nodes (19.9%) and bones (13.2%). In the present study, the most frequent site of extrahepatic metastasis was the lungs, followed by the bones, lymph nodes and adrenal glands, regardless of previous treatment of intrahepatic tumors. These results are similar to those previously reported and suggest that previous treatment does not affect the metastatic pattern of HCC.
Several studies reported that in HCC patients with extrahepatic metastasis, intrahepatic tumor status and Child-Pugh classification are independent prognostic factors (12, 13, 20) . Similarly, in the present study, the multivariate analysis demonstrated that these factors were independent predictors of survival in HCC patients with extrahepatic metastasis, regardless of previous treatment. Sorafenib is an oral systemic agent that prolongs overall survival and has become the standard treatment for patients with advanced HCC, including those with extrahepatic metastasis. However, even the survival rates achieved with sorafenib remain unsatisfactory. Several studies reported that the characteristics of primary tumor progression, such as vascular invasion, tumor size and tumor number, are independent risk factors for extrahepatic metastasis following curative resection (14, 22) . Thus, the control of intrahepatic tumors may be important for the prevention of further extrahepatic metastasis. Pinter et al (23) reported that the MST of TACE alone (9.2 months) was similar to that of sorafenib alone (7.4 months) in patients with advanced HCC, including those with extrahepatic metastasis. Jun et al (14) reported that in 240 HCC patients with extrahepatic metastasis, the control of intrahepatic tumors was a favorable prognostic factor for survival: the MST of patients exhibiting a treatment response was significantly longer compared to that of patients who did not respond to treatment (521 vs. 170 days; P<0.001). Consequently, in advanced HCC patients with extrahepatic metastasis, a combination of intrahepatic local treatments and sorafenib may be useful, as the malignant potential of intrahepatic tumors is associated with extrahepatic spread and survival.
Hepatic reserve is important for hepatic resection and metabolism of anticancer drugs, including sorafenib. Pinter et al (24) reported that the risk of high-grade toxicities associated with sorafenib may be increased in patients with advanced liver dysfunction. Our previous study of advanced HCC patients treated with HAIC demonstrated that liver dysfunction necessitating treatment suspension or discontinuation occurred more frequently in patients with Child-Pugh class B compared to patients with Child-Pugh class A disease (25) . Such insufficient treatment may lead to further liver dysfunction, due to intrahepatic tumor progression, resulting in poor survival. Therefore, we considered liver function to be an important predictor of survival.
In this study, we also demonstrated that an elevated white blood cell count associated with a high NLR was a significant independent predictor of survival in HCC patients with extrahepatic metastasis. Recently, various markers of systemic inflammatory responses, including cytokines, C-reactive protein and absolute blood neutrophil or lymphocyte count, as well as their ratio (including NLR), have been investigated for their prognostic roles in cancer. Of these, NLR is one of the most simple and effective markers of inflammation and is linked with poor prognosis in various cancer types (26) (27) (28) . Several studies demonstrated that an elevated NLR was associated with worse survival in patients with HCC who underwent radiofrequency ablation, TACE, resection and liver transplantation (29) (30) (31) (32) . However, the exact association between a high NLR and poor prognosis has not been fully elucidated. One possible explanation is that patients with an elevated NLR have relative lymphocytopenia, leading to a weaker lymphocyte-mediated immune response to the tumor due to a decreasing T4/T8 ratio (33) . As a result, these patients may experience a more rapid tumor progression and, therefore, have a poor prognosis. Another explanation is that the increased neutrophil numbers may modify and provide an adequate environment for tumor progression and development. Neutrophils have been shown to promote tumor growth and metastasis by secreting chemokines, vascular endothelial growth factor and matrix metalloproteinase-9, which are involved in the angiogenesis that promotes tumor development (34) (35) (36) . Thus, a high neutrophil level may offer a growth advantage for HCC through the increase of these pro-angiogenic factors, resulting in increased extrahepatic metastasis and worse survival in HCC patients.
In conclusion, we demonstrated that there are differences in the clinical characteristics and no significant differences in survival between patients with advanced HCC with extrahepatic metastasis who received and those who did not receive previous treatment. Moreover, we demonstrated that intrahepatic tumor status, Child-Pugh classification, white blood cell count and NLR are independent predictors of survival in HCC patients with extrahepatic metastasis, regardless of previous treatment of intrahepatic tumors.
